Mode
Text Size
Log in / Sign up

BNT162b2 vaccination shows no significant increase in stroke risk in meta-analysisCOVID vaccine not linked to higher stroke risk, analysis finds

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret the lack of significant stroke risk increase as reassuring, but consider methodological heterogeneity.

This is a meta-analysis assessing the risk of stroke following vaccination with BNT162b2. The analysis pooled data from several million vaccinated individuals, focusing on the primary outcome of stroke risk. The pooled effect size was 0.967 with a 95% confidence interval of 0.892 to 1.049, indicating no statistically significant increase in stroke risk. The authors report that heterogeneity was driven by methodological differences among the included studies, which may affect the precision of the estimate.

The findings suggest that at the population level, there is no evidence of increased short-term stroke risk following BNT162b2 vaccination. However, the analysis is limited by the heterogeneity noted, and the confidence interval includes values both below and above 1, so a small increased risk cannot be entirely excluded. The authors do not report on adverse events, serious adverse events, or discontinuations, and the follow-up duration is not specified.

Given the observational nature of the included studies, causality cannot be established, and the association should be interpreted with caution. The results are reassuring but do not rule out rare or long-term risks. Clinicians should weigh these findings alongside other vaccine benefits and risks.

In practice, these results support the safety profile of BNT162b2 with respect to stroke risk, but ongoing surveillance remains important. The meta-analysis underscores the need for standardized methodologies in future studies to reduce heterogeneity and improve confidence in pooled estimates.

How this fits prior evidence

This meta-analysis addresses a gap in prior coverage by examining vaccine safety, specifically stroke risk after BNT162b2 vaccination. Prior coverage focused on stroke therapies and risk prediction, but not on vaccine-related outcomes. The finding of no significant increase in stroke risk (effect size 0.967, 95% CI 0.892-1.049) extends the safety profile of BNT162b2, complementing earlier reports on stroke management and prediction. It does not directly confirm or contrast with prior items, but adds a new dimension to stroke risk factors.

If you've been worried about the COVID-19 vaccine and stroke risk, a new analysis brings reassuring news. Researchers pooled data from several million people who received the Pfizer vaccine, known as BNT162b2, to see if it was linked to a higher chance of having a stroke. The short answer: no.

The analysis found no statistically significant increase in stroke risk after vaccination. The numbers showed a risk ratio of 0.967, with a 95% confidence interval from 0.892 to 1.049. In plain terms, that means the risk of stroke was essentially the same as for people who didn't get the vaccine. The confidence interval includes 1, which means no increased risk was detected.

This is a meta-analysis, a type of study that combines results from many studies to get a clearer picture. The researchers included data from several million people, making this a very large and powerful analysis. However, the study had some limitations. The authors noted that differences in how the studies were designed might have influenced the results, a factor called heterogeneity. This means the findings, while reassuring, aren't the final word.

For most people, this analysis adds to the evidence that the Pfizer vaccine is safe when it comes to stroke risk. But as with any medical decision, it's always a good idea to talk to your doctor if you have specific concerns. This study doesn't prove the vaccine is completely risk-free, but it does suggest that any risk of stroke is not elevated at the population level.

What this means for you:
No increased stroke risk found after Pfizer COVID vaccine in large analysis.

Common questions

Does the Pfizer COVID vaccine increase stroke risk?

Based on this large analysis, no. The study found no statistically significant increase in stroke risk after vaccination with BNT162b2, the Pfizer vaccine. The risk was essentially the same as for people who didn't get the vaccine. This is reassuring news for the millions of people who have received this vaccine.

How many people were in this stroke risk study?

The analysis included data from several million people who received the Pfizer vaccine. This large sample size gives the study strong power to detect even small increases in risk, making the finding of no increased risk more reliable.

What are the limitations of this study on stroke and the COVID vaccine?

The main limitation is that the studies included in the analysis had methodological differences, which could affect the results. This is called heterogeneity. Because of this, the findings should be interpreted with some caution, though they still provide no evidence of increased short-term stroke risk.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
INTRODUCTION: Whether BNT162b2 (Pfizer-BioNTech) vaccination increases stroke risk remains a public health concern. This is the first meta-analysis to synthesize self-controlled case series (SCCS)-derived stroke risk estimates specifically for BNT162b2 vaccination. METHODS: PubMed and Embase were searched from inception through 9 May 2026, following PRISMA 2020 guidelines. Eight eligible SCCS studies were pooled using a random-effects model with restricted maximum likelihood (REML) estimation and the Knapp-Hartung adjustment. RESULTS: Eight studies across six countries encompassing several million vaccinated individuals were included. The pooled incidence rate ratio (IRR) was 0.967 (95% CI 0.892-1.049; I = 69.2%), indicating no statistically significant increase in stroke risk. Subgroup analyses showed no evidence of effect modification across continent, risk-window length, dose category, SCCS variant, or age group. CONCLUSIONS: These findings provide no evidence of increased short-term stroke risk following BNT162b2 vaccination at the population level. The observed heterogeneity appeared to be partly driven by methodological differences rather than true biological variation in vaccine effect.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.